Premium
Alzheimer's Disease Therapeutics: New Approaches to an Ageing Problem
Author(s) -
Small David H.,
Losic Dusan,
Martin Lisandra L.,
Turner Bradley J.,
Friedhuber Anna,
Aguilar MarieIsabel
Publication year - 2004
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1080/15216540410001709211
Subject(s) - amyloid precursor protein secretase , amyloid (mycology) , disease , pathogenesis , amyloid precursor protein , biochemistry of alzheimer's disease , alzheimer's disease , amyloid beta , protease , medicine , neuroscience , pharmacology , chemistry , biology , biochemistry , enzyme , pathology
Abnormal proteinaceous deposits are found in the brain of patients with many different neurodegenerative diseases. In many of these diseases, the production of the deposits is probably associated with disease pathogenesis. In Alzheimer's disease (AD), the amyloid protein (Aβ), is produced by the action of enzymes known as secretases, which cleave the β‐amyloid protein precursor. Aβ is secreted from cells in the brain, after which it oligomerizes and is deposited in the extracellular compartment of the brain to form amyloid plaques and amyloid angiopathy. Targeting the production of Aβ and its aggregation is now a key strategy in the development of novel therapeutic agents for the treatment of AD. This review examines the potential of immunization strategies, cholesterol‐lowering drugs, protease inhibitors and nicotinic drugs for the treatment of AD.IUBMB Life, 56: 203‐208, 2004